07/09/2004
Unpublished cancer trial results impair treatments, says charity
Doctors are not being armed with all the information they need to make treatment decisions because data from clinical trials is being left unpublished and inaccessible, according to the charity Cancer Research UK.
The charity issued its warning after research found that data from over a quarter of cancer clinical trials may never reach the public domain.
Doctors use the results from trials to choose the best treatment for patients – but experts from the charity, speaking at the BA Festival of Science in Exeter, said they were concerned this may be hampered by inaccessible data.
Instead, a comprehensive database of all clinical trials should be established to monitor the progress of research and ensure data is published.
Dr Richard Sullivan, Head of Clinical Programmes at Cancer Research UK, said: "The medical community needs to know the results of clinical trials to be able to view the entire picture of how a treatment works, how it compares to other therapies and what choices could serve patients best.
"It's disturbing to think that important information on clinical trials is being left to gather dust."
One study looked specifically at 500 cancer clinical trials and found that 26% had failed to fully publish five-years after presenting preliminary data at a leading American cancer conference.
Trial investigators cited lack of time and shortage of funds as their main reasons for not publishing.
The study also suggested that investigators may lose interest in trials where the treatment being tested was found to be no better than the standard and can experience difficulties with getting this kind of result published.
Dr Sullivan added: "If only positive results are published this can distort medical literature and leave doctors thinking a treatment is more effective than it actually is. This in turn can affect the validity and findings of subsequent reviews, treatment decisions and clinical practice guidelines."
(gmcg/mb)
The charity issued its warning after research found that data from over a quarter of cancer clinical trials may never reach the public domain.
Doctors use the results from trials to choose the best treatment for patients – but experts from the charity, speaking at the BA Festival of Science in Exeter, said they were concerned this may be hampered by inaccessible data.
Instead, a comprehensive database of all clinical trials should be established to monitor the progress of research and ensure data is published.
Dr Richard Sullivan, Head of Clinical Programmes at Cancer Research UK, said: "The medical community needs to know the results of clinical trials to be able to view the entire picture of how a treatment works, how it compares to other therapies and what choices could serve patients best.
"It's disturbing to think that important information on clinical trials is being left to gather dust."
One study looked specifically at 500 cancer clinical trials and found that 26% had failed to fully publish five-years after presenting preliminary data at a leading American cancer conference.
Trial investigators cited lack of time and shortage of funds as their main reasons for not publishing.
The study also suggested that investigators may lose interest in trials where the treatment being tested was found to be no better than the standard and can experience difficulties with getting this kind of result published.
Dr Sullivan added: "If only positive results are published this can distort medical literature and leave doctors thinking a treatment is more effective than it actually is. This in turn can affect the validity and findings of subsequent reviews, treatment decisions and clinical practice guidelines."
(gmcg/mb)
Related UK National News Stories
Click here for the latest headlines.
07 December 2006
Experts deliver clinical trial report
The expert group established to make recommendations on improving the safety of clinical drug trials has published its final report today.
Experts deliver clinical trial report
The expert group established to make recommendations on improving the safety of clinical drug trials has published its final report today.
08 May 2013
US Firm To Create 100 New Jobs In Swansea
US firm, PRA, has confirmed it is to create 100 new jobs in Swansea. In a press release, the clinical research company said it will see its workforce double in the city, after a £1.29m fund from the Welsh Government. The jobs, which will be for graduate level, will be for a new multilingual help desk.
US Firm To Create 100 New Jobs In Swansea
US firm, PRA, has confirmed it is to create 100 new jobs in Swansea. In a press release, the clinical research company said it will see its workforce double in the city, after a £1.29m fund from the Welsh Government. The jobs, which will be for graduate level, will be for a new multilingual help desk.
13 October 2010
Patients And Doctors Misled By Data On Medicines
According to a comprehensive study of the evidence published on bmj.com today, the drug reboxetine is, overall, an ineffective and potentially harmful antidepressant.
Patients And Doctors Misled By Data On Medicines
According to a comprehensive study of the evidence published on bmj.com today, the drug reboxetine is, overall, an ineffective and potentially harmful antidepressant.
29 January 2010
BMJ Issues Guidelines On Privacy
Guidance just published on the British Medical Journal's website, bmj.com sets out how personal information from clinical trials should be shared to help minimise risks to patient privacy.
BMJ Issues Guidelines On Privacy
Guidance just published on the British Medical Journal's website, bmj.com sets out how personal information from clinical trials should be shared to help minimise risks to patient privacy.
26 February 2008
Report Suggests Anti-depressants Are A Waste Of Time
New-generation anti-depressants are a waste of time, a review of clinical trials has found. The research suggests anti-depressants worked no better than a dummy pill for mildly depressed patients and for most people suffering severe depression.
Report Suggests Anti-depressants Are A Waste Of Time
New-generation anti-depressants are a waste of time, a review of clinical trials has found. The research suggests anti-depressants worked no better than a dummy pill for mildly depressed patients and for most people suffering severe depression.